2023-05-04 16:50:30 ET
- Joint press release ( NASDAQ: JYNT ): Q1 GAAP EPS of $0.15 beats by $0.16 .
- Revenue of $28.5M (+27.2% Y/Y) beats by $0.59M .
- Unrestricted cash was $14.8 million at March 31, 2023, compared to $9.7 million at December 31, 2022. During the first quarter of 2023, cash provided by operating activities was $6.0 million,
-
For 2023, management reiterated financial and clinic opening guidance.
-
Revenue is expected to be between $123.0 million and $128.0 million, compared to $101.9 million in 2022.
-
Adjusted EBITDA is expected to be between $12.5 million and $14.0 million, compared to $11.5 million in 2022.
-
Franchised clinic openings are expected to be between 100 and 120, compared to 121 in 2022.
-
Company-owned or managed greenfield clinic openings are expected to be between 8 and 12, compared to 16 in 2022.
For further details see:
Joint GAAP EPS of $0.15 beats by $0.16, revenue of $28.5M beats by $0.59M